In this study, we analyzed 4493 premenopausal women with early‐stage estrogen‐receptor breast cancer to see how taking tamoxifen with certain enzyme‐inhibiting drugs (CYP2D6, CYP2C19, and CYP3A4 inhibitors) affected the risk of cancer recurrence. Here, CYP3A4 is linked to breast carcinoma.